within Pharmacolibrary.Drugs.ATC.B;

model B05AA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 10000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.007,
    k12             = 6.0,
    k21             = 6.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Albumin is a major plasma protein produced by the liver, commonly used therapeutically as a plasma volume expander in the management of shock, burns, hypoalbuminemia, and other conditions associated with low blood volume or pressure. It is approved for clinical use and is listed on the WHO Model List of Essential Medicines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for intravenous administration of human serum albumin in healthy adult subjects.</p><h4>References</h4><ol><li><p>Kim, K, &amp; Phelps, MA (2023). Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. <i>Clinical pharmacokinetics</i> 62(6) 789–806. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01240-8\">10.1007/s40262-023-01240-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37129750/\">https://pubmed.ncbi.nlm.nih.gov/37129750</a></p></li><li><p>Heinemann, G, et al., &amp; Vogt, W (2003). Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution. <i>British journal of clinical pharmacology</i> 55(3) 241–245. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2003.01711.x\">10.1046/j.1365-2125.2003.01711.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12630973/\">https://pubmed.ncbi.nlm.nih.gov/12630973</a></p></li><li><p>Klinkmann, G, et al., &amp; Mitzner, S (2022). Impact of Albumin Binding Function on Pharmacokinetics and Pharmacodynamics of Furosemide. <i>Medicina (Kaunas, Lithuania)</i> 58(12) –. DOI:<a href=\"https://doi.org/10.3390/medicina58121780\">10.3390/medicina58121780</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36556982/\">https://pubmed.ncbi.nlm.nih.gov/36556982</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AA01;
